Lung Cancer Trial, By Invitation NCT07122882 Sponsor: Chang Gung Memorial Hospital Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, By Invitation

NCT07122882
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer), confirmed by laboratory testing of tissue, and who have at least one of the following known gene changes before starting systemic treatment: EGFR exon 18-21, MET exon-14-skipping, ERBB2, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600, or KRAS G12C.
  • People whose cancer has been assessed by their treating doctor as having progressed (gotten worse) after receiving a targeted drug treatment known as a tyrosine kinase inhibitor (TKI).
  • People who have tumor tissue available that can be used for genetic testing.
  • People who are able to have a blood sample taken for genetic testing.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have not received a TKI targeted drug treatment, or whose medical records do not show that their cancer progressed while on that treatment.
  • People whose tumor tissue is not available, or whose tumor tissue DNA is not of sufficient quality for genetic testing.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
11 May 2027

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Genomic alterations associated with resistance to TKI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov